EGFR Exon 20 Insertion NSCLC: A Comprehensive Overview
Experts discuss the rapidly evolving treatment landscape for EGFR exon 20 insertion lung cancer, highlighting recent advancements in therapies, clinical trial results, and the quest for first-line treatment options, providing valuable insights into managing this unique patient population.
EP: 1.Biomarker Testing and Advancements in EGFR-Mutant NSCLC Treatment Strategies
EP: 2.Revolutionizing First-Line Strategies in EGFR-Mutant NSCLC: Combination Therapies
EP: 3.Impact of Combination Therapies and CNS Efficacy in EGFR-Mutant NSCLC Treatment
EP: 4.EGFR-Mutant NSCLC: Second-Line Treatment Options and Safety Data
EP: 5.Advancements in EGFR-Mutant NSCLC: ADCs and Other Targeted Therapies
Now Viewing
EP: 6.EGFR Exon 20 Insertion NSCLC: A Comprehensive Overview
EP: 7.Unmet Needs in EGFR Exon 20 Insertion Non–Small Cell Lung Cancer
EP: 8.“Exciting Year” for Targeted Therapy Options for Mutated NSCLC, Experts Say
Recent Videos
Related Content
Neoadjuvant Capecitabine Plus Temozolomide in Atypical Lung NETs
Georgios Evangelou, MD, MSc;Ioannis Vamvakaris, MD, PhD, MSc;Irene Konstantopoulou, PhD;Konstantinos Syrigos, PhD
July 10th 2024Article
Read about a woman with well-differentiated atypical carcinoid who experienced a 21% regression in primary tumor size after 12 months on neoadjuvant capecitabine and temozolomide.
